A 68-year-old man with chronic obstructive pulmonary disease (COPD) and smoking history presents with insidious onset cough, low-grade fever, and patchy infiltrates in multiple lobes on chest X-ray. Sputum culture grows *Haemophilus influenzae*. What is the drug of choice for bronchopneumonia in this patient?

Explanation

## Bronchopneumonia — First-Line Treatment ### Clinical Context Bronchopneumonia presents with insidious onset, patchy multilobar infiltrates, and is common in elderly, debilitated, or COPD patients. *Haemophilus influenzae* is a frequent pathogen in bronchopneumonia, especially in COPD. ### Drug of Choice **Key Point:** Amoxicillin-clavulanate is the first-line oral or IV agent for bronchopneumonia caused by *H. influenzae* and other gram-negative organisms in community-acquired settings. ### Why Amoxicillin-Clavulanate? 1. **Beta-lactamase coverage** — clavulanic acid protects amoxicillin from *H. influenzae* beta-lactamase 2. **Excellent oral bioavailability** — suitable for step-down therapy after initial IV cephalosporin 3. **Adequate for non-invasive disease** — bronchopneumonia is typically non-bacteremic 4. **Cost-effective** — preferred in resource-limited settings for mild-to-moderate CAP ### Lobar vs Bronchopneumonia — Treatment Paradigm | Feature | Lobar Pneumonia | Bronchopneumonia | |---------|-----------------|------------------| | **Onset** | Acute, sudden | Insidious | | **Consolidation** | Single lobe | Patchy, multilobar | | **Bacteremia** | Common (40–50%) | Rare | | **Typical organism** | *S. pneumoniae* | *H. influenzae*, gram-negatives | | **First-line drug** | Ceftriaxone (IV) | Amoxicillin-clavulanate (oral/IV) | | **Patient profile** | Young, healthy | Elderly, COPD, debilitated | ### High-Yield Distinction **High-Yield:** Lobar pneumonia → Cephalosporin (ceftriaxone). Bronchopneumonia → Amoxicillin-clavulanate (covers *H. influenzae* beta-lactamase). ### Clinical Pearl **Clinical Pearl:** In COPD patients with bronchopneumonia, amoxicillin-clavulanate provides adequate coverage for *H. influenzae*, *S. pneumoniae*, and *M. catarrhalis* without the need for IV third-generation cephalosporins. Oral therapy is often sufficient if the patient can tolerate it.